- Huadong Medicine’s net income for the first half of 2024 reached 1.70 billion yuan, marking a 19% increase year-over-year.
- The company’s revenue for the same period was 20.97 billion yuan, showing a 2.8% rise from the previous year.
- Analyst ratings for Huadong Medicine include 25 buys, 1 hold, and 1 sell.
- Comparisons to past results are derived from the company’s original disclosures.
A look at Huadong Medicine Co Ltd A Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 4 | |
| Growth | 4 | |
| Resilience | 3 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Smart Scores indicate a positive long-term outlook for Huadong Medicine Co Ltd A. With a solid score of 4 for both Dividend and Growth, the company is positioned well for steady returns and expansion. Additionally, scoring a 3 for Value reflects a reasonably priced investment opportunity, making it potentially attractive for value investors. Coupled with a Momentum score of 4, Huadong Medicine Co Ltd A is showing strong performance trends that could continue to drive its growth in the future.
Huadong Medicine Co Ltd A, a company specializing in wholesaling and retailing medicines, pharmaceutical preparations, biological products, and medical instruments, demonstrates resilience with a score of 3, implying its ability to withstand market uncertainties. Overall, the company’s Smart Scores paint a favorable picture for its long-term prospects, indicating a balanced combination of value, growth, dividend yield, resilience, and momentum.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
